BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25079699)

  • 1. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.
    Volokhina EB; Westra D; van der Velden TJ; van de Kar NC; Mollnes TE; van den Heuvel LP
    Clin Exp Immunol; 2015 Aug; 181(2):306-13. PubMed ID: 25079699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
    Westra D; Volokhina EB; van der Molen RG; van der Velden TJ; Jeronimus-Klaasen A; Goertz J; Gracchi V; Dorresteijn EM; Bouts AH; Keijzer-Veen MG; van Wijk JA; Bakker JA; Roos A; van den Heuvel LP; van de Kar NC
    Pediatr Nephrol; 2017 Feb; 32(2):297-309. PubMed ID: 27718086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
    Hyvärinen S; Meri S; Jokiranta TS
    Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.
    Åkesson A; Blom AM; Klintman J; Zetterberg E
    Nephrology (Carlton); 2017 Jul; 22(7):555-561. PubMed ID: 27175932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M; Go RS; Willrich MAV
    J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS).
    Watson R; Wearmouth E; McLoughlin AC; Jackson A; Ward S; Bertram P; Bennaceur K; Barker CE; Pappworth IY; Kavanagh D; Lea SM; Atkinson JP; Goodship TH; Marchbank KJ
    Mol Immunol; 2015 Feb; 63(2):287-96. PubMed ID: 25150608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding.
    Volokhina E; Westra D; Xue X; Gros P; van de Kar N; van den Heuvel L
    Pediatr Nephrol; 2012 Sep; 27(9):1519-24. PubMed ID: 22669319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
    Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C
    Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
    Noris M; Galbusera M; Gastoldi S; Macor P; Banterla F; Bresin E; Tripodo C; Bettoni S; Donadelli R; Valoti E; Tedesco F; Amore A; Coppo R; Ruggenenti P; Gotti E; Remuzzi G
    Blood; 2014 Sep; 124(11):1715-26. PubMed ID: 25037630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele
    Pouw RB; Gómez Delgado I; López Lera A; Rodríguez de Córdoba S; Wouters D; Kuijpers TW; Sánchez-Corral P
    Front Immunol; 2018; 9():848. PubMed ID: 29740447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement factor H functional assay may help to monitor atypical haemolytic uraemic syndrome: a pilot study.
    Massart A; Golmarvi S; Hachimi-Idrissi S; Broeders E; Tournay Y; Nortier J; Abramowicz D; Tielemans C; Stordeur P
    Acta Clin Belg; 2013; 68(1):9-14. PubMed ID: 23627188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
    Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
    Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling complement activation on human glomerular microvascular endothelial cells.
    Stevens KH; Baas LM; van der Velden TJAM; Bouwmeester RN; van Dillen N; Dorresteijn EM; van Zuilen AD; Wetzels JFM; Michels MAHM; van de Kar NCAJ; van den Heuvel LP
    Front Immunol; 2023; 14():1206409. PubMed ID: 37954621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.
    Mohlin FC; Nilsson SC; Levart TK; Golubovic E; Rusai K; Müller-Sacherer T; Arbeiter K; Pállinger É; Szarvas N; Csuka D; Szilágyi Á; Villoutreix BO; Prohászka Z; Blom AM
    Mol Immunol; 2015 Jun; 65(2):367-76. PubMed ID: 25733390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-complement-factor H-associated glomerulopathies.
    Durey MA; Sinha A; Togarsimalemath SK; Bagga A
    Nat Rev Nephrol; 2016 Sep; 12(9):563-78. PubMed ID: 27452363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
    Huerta A; Arjona E; Portoles J; Lopez-Sanchez P; Rabasco C; Espinosa M; Cavero T; Blasco M; Cao M; Manrique J; Cabello-Chavez V; Suñer M; Heras M; Fulladosa X; Belmar L; Sempere A; Peralta C; Castillo L; Arnau A; Praga M; Rodriguez de Cordoba S
    Kidney Int; 2018 Feb; 93(2):450-459. PubMed ID: 28911789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.